Nichole Tucker

Articles

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

September 8th 2021

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors

June 8th 2021

The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.

SD-101 Plus Pembrolizumab and Paclitaxel Yields Moderate Response Boost in High-Risk, HER2-Negative Breast Cancer

June 7th 2021

Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.

Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma

June 5th 2021

Allogeneic hematopoietic cell transplantation was safe when used with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma.

Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis

April 11th 2021

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

Maintenance Niraparib Maintains PFS Improvement in gBRCA+/- Ovarian Cancer

March 22nd 2021

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Ruxolitinib Showcases Early Efficacy, Safety in Pediatric Chronic GVHD

February 9th 2021

February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.

Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC

January 31st 2021

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.

Anlotinib Induces PFS Benefit in RAS/BRAF Wildtype+ mCRC

January 15th 2021

January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.

Ki-67 Can Be Used to Select Abemaciclib for Patients With High-Risk Early Breast Cancer

December 10th 2020

December 10, 2020 - Treatment with abemaciclib in combination with endocrine therapy significantly reduced the risk of invasive disease recurrence or death in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who had high Ki-67 tumors, suggesting that this feature can be used in conjunction with high-risk features to select patients for abemaciclib in the adjuvant setting.

Brentuximab Vedotin Shows Encouraging Responses Rates, Tolerability in Older Patients With Hodgkin Lymphoma

December 8th 2020

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

Ponatinib Elicits High Responses, Robust Outcomes in CP-CML Following TKI Failure

December 8th 2020

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

CD47-Directed TTI-622 Elicits Early Efficacy Signals in Relapsed/Refractory Lymphoma

December 6th 2020

December 6, 2020 — TTI-622, an investigational CD47 inhibitor, showed preliminary signs of clinical activity with a manageable safety profile among patients with relapsed/refractory lymphoma.

Early Allogeneic HSCT With HLA-Matched Donor Improves Outcomes in Older Patients With Higher-Risk MDS

December 6th 2020

December 6, 2020 - Having a human leukocyte antigen–matching donor for allogeneic hematopoietic stem cell transplant has proven to lead to improved outcomes for patients who are between 50 and 75 years of age and have higher-risk myelodysplastic syndrome.

Oral Azacitidine Improves Health-Related QoL in AML

December 6th 2020

Oral azacitidine demonstrated sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

September 20th 2020

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.